Brief: Lantern Pharma Announces First Patient Dosed In Phase 2 Study, Harmonic, For Lp-300 In Never Smokers With Advanced Non-Small Cell Lung Cancer
28/03/2023 13:22
March 28 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA ANNOUNCES FIRST PATIENT DOSED IN THE PHASE
2
STUDY, HARMONIC™, FOR LP-300 IN NEVER SMOKERS WITH ADVANCED
NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nBw1lTS2Qa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments